FIELD: medicine.
SUBSTANCE: gene therapy of malignant growths involves a recombinant genetically engineered construct containing an upstream promoter sequence of human gene NDUFV1 of the length of 3574 base pairs with a remote proximal sequence of the length of 91 base pairs and a controlled effector therapeutic cytotoxic gene, as well as the recombinant genetically engineered construct containing the upstream promoter sequence of human gene NDUFV1 of the length of 3574 base pairs with the remote proximal sequence of the length of 91 base pairs and a transposase gene under its transcription control in molar relation 100:1-1:100.
EFFECT: invention provides extended range of products for genetic therapy of various malignant growths caused by terminal cell growth.
3 dwg, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROMOTER FOR TISSUE-SPECIFIC GENE EXPRESSION IN TERMINAL MAMMAL TISSUES | 2010 |
|
RU2459870C2 |
| TRANSPOSASE POLYPEPTIDES AND USE THEREOF | 2016 |
|
RU2735700C2 |
| GENETIC MAKE-UPS FOR ANTI-HIV THERAPY | 2010 |
|
RU2426788C1 |
| MULTIPURPOSE CANCER-SPECIFIC PROMOTERS AND USING THEM IN ANTI-CANCER THERAPY | 2013 |
|
RU2539764C2 |
| IMPROVING GENETIC CONSTRUCTS FOR PROVIDING HIGH EFFICACY OF ANTI-HIV THERAPY | 2013 |
|
RU2533817C1 |
| IMPROVED TRANSGENE EXPRESSION AND PROCESSING | 2014 |
|
RU2808756C1 |
| RECOMBINANT PLASMID DNA LENTI sgRNA(MS2)_zeo_Myc, PROVIDING ACTIVATION OF Myc GENE EXPRESSION IN HUMAN CELLS, METHOD OF OBTAINING HUMAN CELLS WITH STABLY INCREASED EXPRESSION OF Myc GENE AND MONOCLONAL HUMAN BREAST CANCER CELL LINE BT549_Myc WITH STABLY INCREASED EXPRESSION OF Myc GENE | 2022 |
|
RU2812975C1 |
| METHOD OF PRODUCING PROTEIN | 2010 |
|
RU2563514C2 |
| VIRAL VECTOR MANUFACTURE | 2014 |
|
RU2658487C2 |
| B-CELLS FOR IN VIVO THERAPEUTIC DELIVERY AND THEIR DOSES | 2018 |
|
RU2812477C2 |
